Viromed Medical AG
Viromed Medical AG engages in the development and distribution of products in diagnostics, therapeutics, and cold plasma technology. The company was formerly known as Fonterelli SPAC2 AG. Viromed Medical AG was incorporated in 2021 and is based in Pinneberg, Germany.
Viromed Medical AG (Q11) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.038x
Based on the latest financial reports, Viromed Medical AG (Q11) has a cash flow conversion efficiency ratio of -0.038x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-10.12 Million) by net assets (€269.20 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Viromed Medical AG - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how Viromed Medical AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Viromed Medical AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Viromed Medical AG ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
RYOTF
PINK:RYOTF
|
N/A |
|
QINETIQ GROUP - Dusseldorf Stock Exchang
DU:QY6
|
N/A |
|
THG Holdings PLC
LSE:THG
|
-0.134x |
|
Turn Cloud Technology Service Inc.
TWO:6870
|
N/A |
|
Signet EV Inc
KO:260870
|
N/A |
|
CITYDEV (CDE.SG)
STU:CDE
|
0.029x |
|
AEM
AT:AEM
|
N/A |
|
Hyundai Pharmaceutical Co. Ltd.
KQ:004310
|
N/A |
Annual Cash Flow Conversion Efficiency for Viromed Medical AG (2021–2024)
The table below shows the annual cash flow conversion efficiency of Viromed Medical AG from 2021 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €201.16 Million | €-6.03 Million | -0.030x | +94.36% |
| 2023-12-31 | €64.28 Million | €-34.16 Million | -0.531x | -60.96% |
| 2022-12-31 | €63.23 Million | €-20.87 Million | -0.330x | +40.80% |
| 2021-12-31 | €39.97 Million | €-22.29 Million | -0.558x | -- |